Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls
<p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Fin...
Ausführliche Beschreibung
Autor*in: |
Robson Mark [verfasserIn] Satagopan Jaya [verfasserIn] Huang Helen [verfasserIn] Yossepowitch Orit [verfasserIn] Johnson Steven [verfasserIn] Gregersen Peter [verfasserIn] Rapaport Beth [verfasserIn] Kolachana Prema [verfasserIn] Kirchhoff Tomas [verfasserIn] Pierce Heather [verfasserIn] Offit Kenneth [verfasserIn] Scheuer Lauren [verfasserIn] Nafa Khedoudja [verfasserIn] Ellis Nathan [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2003 |
---|
Übergeordnetes Werk: |
In: BMC Medical Genetics - BMC, 2003, 4(2003), 1, p 1 |
---|---|
Übergeordnetes Werk: |
volume:4 ; year:2003 ; number:1, p 1 |
Links: |
---|
DOI / URN: |
10.1186/1471-2350-4-1 |
---|
Katalog-ID: |
DOAJ049878883 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ049878883 | ||
003 | DE-627 | ||
005 | 20230308145624.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2003 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/1471-2350-4-1 |2 doi | |
035 | |a (DE-627)DOAJ049878883 | ||
035 | |a (DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC31-1245 | |
050 | 0 | |a QH426-470 | |
100 | 0 | |a Robson Mark |e verfasserin |4 aut | |
245 | 1 | 0 | |a Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls |
264 | 1 | |c 2003 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a <p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< | ||
653 | 0 | |a Internal medicine | |
653 | 0 | |a Genetics | |
700 | 0 | |a Satagopan Jaya |e verfasserin |4 aut | |
700 | 0 | |a Huang Helen |e verfasserin |4 aut | |
700 | 0 | |a Yossepowitch Orit |e verfasserin |4 aut | |
700 | 0 | |a Johnson Steven |e verfasserin |4 aut | |
700 | 0 | |a Gregersen Peter |e verfasserin |4 aut | |
700 | 0 | |a Rapaport Beth |e verfasserin |4 aut | |
700 | 0 | |a Kolachana Prema |e verfasserin |4 aut | |
700 | 0 | |a Kirchhoff Tomas |e verfasserin |4 aut | |
700 | 0 | |a Pierce Heather |e verfasserin |4 aut | |
700 | 0 | |a Offit Kenneth |e verfasserin |4 aut | |
700 | 0 | |a Scheuer Lauren |e verfasserin |4 aut | |
700 | 0 | |a Nafa Khedoudja |e verfasserin |4 aut | |
700 | 0 | |a Ellis Nathan |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t BMC Medical Genetics |d BMC, 2003 |g 4(2003), 1, p 1 |w (DE-627)326643788 |w (DE-600)2041359-2 |x 14712350 |7 nnns |
773 | 1 | 8 | |g volume:4 |g year:2003 |g number:1, p 1 |
856 | 4 | 0 | |u https://doi.org/10.1186/1471-2350-4-1 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d |z kostenfrei |
856 | 4 | 0 | |u http://www.biomedcentral.com/1471-2350/4/1 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1471-2350 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 4 |j 2003 |e 1, p 1 |
author_variant |
r m rm s j sj h h hh y o yo j s js g p gp r b rb k p kp k t kt p h ph o k ok s l sl n k nk e n en |
---|---|
matchkey_str |
article:14712350:2003----::rqecoice210ectneyrbescne |
hierarchy_sort_str |
2003 |
callnumber-subject-code |
RC |
publishDate |
2003 |
allfields |
10.1186/1471-2350-4-1 doi (DE-627)DOAJ049878883 (DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d DE-627 ger DE-627 rakwb eng RC31-1245 QH426-470 Robson Mark verfasserin aut Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< Internal medicine Genetics Satagopan Jaya verfasserin aut Huang Helen verfasserin aut Yossepowitch Orit verfasserin aut Johnson Steven verfasserin aut Gregersen Peter verfasserin aut Rapaport Beth verfasserin aut Kolachana Prema verfasserin aut Kirchhoff Tomas verfasserin aut Pierce Heather verfasserin aut Offit Kenneth verfasserin aut Scheuer Lauren verfasserin aut Nafa Khedoudja verfasserin aut Ellis Nathan verfasserin aut In BMC Medical Genetics BMC, 2003 4(2003), 1, p 1 (DE-627)326643788 (DE-600)2041359-2 14712350 nnns volume:4 year:2003 number:1, p 1 https://doi.org/10.1186/1471-2350-4-1 kostenfrei https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d kostenfrei http://www.biomedcentral.com/1471-2350/4/1 kostenfrei https://doaj.org/toc/1471-2350 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2003 1, p 1 |
spelling |
10.1186/1471-2350-4-1 doi (DE-627)DOAJ049878883 (DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d DE-627 ger DE-627 rakwb eng RC31-1245 QH426-470 Robson Mark verfasserin aut Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< Internal medicine Genetics Satagopan Jaya verfasserin aut Huang Helen verfasserin aut Yossepowitch Orit verfasserin aut Johnson Steven verfasserin aut Gregersen Peter verfasserin aut Rapaport Beth verfasserin aut Kolachana Prema verfasserin aut Kirchhoff Tomas verfasserin aut Pierce Heather verfasserin aut Offit Kenneth verfasserin aut Scheuer Lauren verfasserin aut Nafa Khedoudja verfasserin aut Ellis Nathan verfasserin aut In BMC Medical Genetics BMC, 2003 4(2003), 1, p 1 (DE-627)326643788 (DE-600)2041359-2 14712350 nnns volume:4 year:2003 number:1, p 1 https://doi.org/10.1186/1471-2350-4-1 kostenfrei https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d kostenfrei http://www.biomedcentral.com/1471-2350/4/1 kostenfrei https://doaj.org/toc/1471-2350 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2003 1, p 1 |
allfields_unstemmed |
10.1186/1471-2350-4-1 doi (DE-627)DOAJ049878883 (DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d DE-627 ger DE-627 rakwb eng RC31-1245 QH426-470 Robson Mark verfasserin aut Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< Internal medicine Genetics Satagopan Jaya verfasserin aut Huang Helen verfasserin aut Yossepowitch Orit verfasserin aut Johnson Steven verfasserin aut Gregersen Peter verfasserin aut Rapaport Beth verfasserin aut Kolachana Prema verfasserin aut Kirchhoff Tomas verfasserin aut Pierce Heather verfasserin aut Offit Kenneth verfasserin aut Scheuer Lauren verfasserin aut Nafa Khedoudja verfasserin aut Ellis Nathan verfasserin aut In BMC Medical Genetics BMC, 2003 4(2003), 1, p 1 (DE-627)326643788 (DE-600)2041359-2 14712350 nnns volume:4 year:2003 number:1, p 1 https://doi.org/10.1186/1471-2350-4-1 kostenfrei https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d kostenfrei http://www.biomedcentral.com/1471-2350/4/1 kostenfrei https://doaj.org/toc/1471-2350 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2003 1, p 1 |
allfieldsGer |
10.1186/1471-2350-4-1 doi (DE-627)DOAJ049878883 (DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d DE-627 ger DE-627 rakwb eng RC31-1245 QH426-470 Robson Mark verfasserin aut Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< Internal medicine Genetics Satagopan Jaya verfasserin aut Huang Helen verfasserin aut Yossepowitch Orit verfasserin aut Johnson Steven verfasserin aut Gregersen Peter verfasserin aut Rapaport Beth verfasserin aut Kolachana Prema verfasserin aut Kirchhoff Tomas verfasserin aut Pierce Heather verfasserin aut Offit Kenneth verfasserin aut Scheuer Lauren verfasserin aut Nafa Khedoudja verfasserin aut Ellis Nathan verfasserin aut In BMC Medical Genetics BMC, 2003 4(2003), 1, p 1 (DE-627)326643788 (DE-600)2041359-2 14712350 nnns volume:4 year:2003 number:1, p 1 https://doi.org/10.1186/1471-2350-4-1 kostenfrei https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d kostenfrei http://www.biomedcentral.com/1471-2350/4/1 kostenfrei https://doaj.org/toc/1471-2350 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2003 1, p 1 |
allfieldsSound |
10.1186/1471-2350-4-1 doi (DE-627)DOAJ049878883 (DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d DE-627 ger DE-627 rakwb eng RC31-1245 QH426-470 Robson Mark verfasserin aut Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< Internal medicine Genetics Satagopan Jaya verfasserin aut Huang Helen verfasserin aut Yossepowitch Orit verfasserin aut Johnson Steven verfasserin aut Gregersen Peter verfasserin aut Rapaport Beth verfasserin aut Kolachana Prema verfasserin aut Kirchhoff Tomas verfasserin aut Pierce Heather verfasserin aut Offit Kenneth verfasserin aut Scheuer Lauren verfasserin aut Nafa Khedoudja verfasserin aut Ellis Nathan verfasserin aut In BMC Medical Genetics BMC, 2003 4(2003), 1, p 1 (DE-627)326643788 (DE-600)2041359-2 14712350 nnns volume:4 year:2003 number:1, p 1 https://doi.org/10.1186/1471-2350-4-1 kostenfrei https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d kostenfrei http://www.biomedcentral.com/1471-2350/4/1 kostenfrei https://doaj.org/toc/1471-2350 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2003 1, p 1 |
language |
English |
source |
In BMC Medical Genetics 4(2003), 1, p 1 volume:4 year:2003 number:1, p 1 |
sourceStr |
In BMC Medical Genetics 4(2003), 1, p 1 volume:4 year:2003 number:1, p 1 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Internal medicine Genetics |
isfreeaccess_bool |
true |
container_title |
BMC Medical Genetics |
authorswithroles_txt_mv |
Robson Mark @@aut@@ Satagopan Jaya @@aut@@ Huang Helen @@aut@@ Yossepowitch Orit @@aut@@ Johnson Steven @@aut@@ Gregersen Peter @@aut@@ Rapaport Beth @@aut@@ Kolachana Prema @@aut@@ Kirchhoff Tomas @@aut@@ Pierce Heather @@aut@@ Offit Kenneth @@aut@@ Scheuer Lauren @@aut@@ Nafa Khedoudja @@aut@@ Ellis Nathan @@aut@@ |
publishDateDaySort_date |
2003-01-01T00:00:00Z |
hierarchy_top_id |
326643788 |
id |
DOAJ049878883 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ049878883</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308145624.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2003 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1471-2350-4-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ049878883</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH426-470</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Robson Mark</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2003</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Genetics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satagopan Jaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huang Helen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yossepowitch Orit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Johnson Steven</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gregersen Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rapaport Beth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kolachana Prema</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kirchhoff Tomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierce Heather</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Offit Kenneth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Scheuer Lauren</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nafa Khedoudja</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ellis Nathan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Medical Genetics</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">4(2003), 1, p 1</subfield><subfield code="w">(DE-627)326643788</subfield><subfield code="w">(DE-600)2041359-2</subfield><subfield code="x">14712350</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:1, p 1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1471-2350-4-1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.biomedcentral.com/1471-2350/4/1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2350</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2003</subfield><subfield code="e">1, p 1</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Robson Mark |
spellingShingle |
Robson Mark misc RC31-1245 misc QH426-470 misc Internal medicine misc Genetics Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls |
authorStr |
Robson Mark |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)326643788 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC31-1245 |
illustrated |
Not Illustrated |
issn |
14712350 |
topic_title |
RC31-1245 QH426-470 Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls |
topic |
misc RC31-1245 misc QH426-470 misc Internal medicine misc Genetics |
topic_unstemmed |
misc RC31-1245 misc QH426-470 misc Internal medicine misc Genetics |
topic_browse |
misc RC31-1245 misc QH426-470 misc Internal medicine misc Genetics |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
BMC Medical Genetics |
hierarchy_parent_id |
326643788 |
hierarchy_top_title |
BMC Medical Genetics |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)326643788 (DE-600)2041359-2 |
title |
Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls |
ctrlnum |
(DE-627)DOAJ049878883 (DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d |
title_full |
Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls |
author_sort |
Robson Mark |
journal |
BMC Medical Genetics |
journalStr |
BMC Medical Genetics |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2003 |
contenttype_str_mv |
txt |
author_browse |
Robson Mark Satagopan Jaya Huang Helen Yossepowitch Orit Johnson Steven Gregersen Peter Rapaport Beth Kolachana Prema Kirchhoff Tomas Pierce Heather Offit Kenneth Scheuer Lauren Nafa Khedoudja Ellis Nathan |
container_volume |
4 |
class |
RC31-1245 QH426-470 |
format_se |
Elektronische Aufsätze |
author-letter |
Robson Mark |
doi_str_mv |
10.1186/1471-2350-4-1 |
author2-role |
verfasserin |
title_sort |
frequency of <it<chek2*1100delc</it< in new york breast cancer cases and controls |
callnumber |
RC31-1245 |
title_auth |
Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls |
abstract |
<p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< |
abstractGer |
<p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< |
abstract_unstemmed |
<p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p< |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1, p 1 |
title_short |
Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls |
url |
https://doi.org/10.1186/1471-2350-4-1 https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d http://www.biomedcentral.com/1471-2350/4/1 https://doaj.org/toc/1471-2350 |
remote_bool |
true |
author2 |
Satagopan Jaya Huang Helen Yossepowitch Orit Johnson Steven Gregersen Peter Rapaport Beth Kolachana Prema Kirchhoff Tomas Pierce Heather Offit Kenneth Scheuer Lauren Nafa Khedoudja Ellis Nathan |
author2Str |
Satagopan Jaya Huang Helen Yossepowitch Orit Johnson Steven Gregersen Peter Rapaport Beth Kolachana Prema Kirchhoff Tomas Pierce Heather Offit Kenneth Scheuer Lauren Nafa Khedoudja Ellis Nathan |
ppnlink |
326643788 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/1471-2350-4-1 |
callnumber-a |
RC31-1245 |
up_date |
2024-07-04T01:10:47.277Z |
_version_ |
1803608860693364736 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ049878883</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308145624.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2003 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1471-2350-4-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ049878883</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa5e9aa2ad7844f43888a0e616e957f2d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH426-470</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Robson Mark</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequency of <it<CHEK2*1100delC</it< in New York breast cancer cases and controls</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2003</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<The <it<1100delC CHEK2 </it<allele has been associated with a 1.4–4.7 fold increased risk for breast cancer in women carrying this mutation. While the frequency of <it<1100delC </it<was 1.1–1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear.</p< <p<Methods</p< <p<We genotyped 1665 healthy New York volunteers and 300 cases of breast cancer for the <it<CHEK2*1100delC</it<.</p< <p<Results</p< <p<The overall frequency of the <it<1100delC </it<was 3/300 (1.0%) among all cases with either a family history of breast cancer (n = 192) or a personal history of breast cancer (n = 108, of which 46 were bilateral, 46 unilateral, and 16 were male breast cancer cases), compared to a frequency of 5/1665 (0.3%) in healthy controls (p = 0.1). There was no difference in allele frequency among Ashkenazi and non-Ashkenazi controls.</p< <p<Conclusion</p< <p<The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for <it<CHEK2*1100delC </it<in North American kindreds.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Genetics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satagopan Jaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huang Helen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yossepowitch Orit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Johnson Steven</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gregersen Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rapaport Beth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kolachana Prema</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kirchhoff Tomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierce Heather</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Offit Kenneth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Scheuer Lauren</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nafa Khedoudja</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ellis Nathan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Medical Genetics</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">4(2003), 1, p 1</subfield><subfield code="w">(DE-627)326643788</subfield><subfield code="w">(DE-600)2041359-2</subfield><subfield code="x">14712350</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:1, p 1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1471-2350-4-1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a5e9aa2ad7844f43888a0e616e957f2d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.biomedcentral.com/1471-2350/4/1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2350</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2003</subfield><subfield code="e">1, p 1</subfield></datafield></record></collection>
|
score |
7.3987207 |